#USA #healthcare #Atlanta #Artivion #Aortic Disease

Artivion to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Artivion, Inc. (NYSE: AORT), a prominent name in cardiac and vascular surgery, has officially announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. This significant event will take place on September 10, 2025, at the Sheraton New York Times Square Hotel, where Artivion will feature in a focused fireside chat scheduled to begin at 2:35 PM ET.

This conference serves as a notable platform for introducing and discussing innovative solutions in the healthcare sector, particularly in addressing complex aortic diseases. Artivion's commitment to providing advanced treatments reinforces its role as a key player in the medical device field.

Live Webcast and Archived Content

For those unable to attend in person, Artivion will facilitate a live webcast of the entire session, which will be accessible through the company’s official website, www.artivion.com, in the Investors section. Additionally, an archived version of the webcast will be made available for 90 days post-event, allowing interested parties to view the discussions at their convenience.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is dedicated to overcoming the challenges faced by cardiac and vascular surgeons while treating patients with aortic diseases. The company has developed an impressive suite of products aiming to enhance surgical outcomes and improve patient care. Artivion's product lineup includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.

With a strong presence in more than 100 countries, Artivion continues to expand its market reach and enhance its innovations geared towards improving patient outcomes in cardiovascular treatments.

The Path Forward

As the healthcare landscape evolves, events such as the Morgan Stanley Healthcare Conference allow companies like Artivion to showcase their latest advancements while networking with industry leaders and stakeholders. The discussions held during the conference will likely impact future collaborations, investments, and research initiatives aimed at advancing cardiac and vascular care.

In conclusion, Artivion looks forward to engaging with attendees and sharing insights that reflect its commitment to excellence in medical device innovation. For further information about the company and its pioneering solutions, visit www.Artivion.com.

Stay tuned for more updates following the conference, as Artivion continues to lead the charge in addressing aortic conditions and elevating the standards of healthcare.